StreetInsider.com News Articles

Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses

Wed, 05 Aug 2026 09:02:00 -0400

HIGHLIGHTS

Preliminary assessment of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose cohorts

Nineteen participants from the SECuRE trial (NCT04868604)^[1] were included in this assessment of the safety and efficacy of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from the ongoing Cohort Expansion phase (data cut-off: July 20, 2026). The SECuRE trial continues to recruit new and treat existing participants in the Cohort Expansion phase.
Prostate-specific antigen (PSA) declines were substantial with 74% of evaluable participants at data cut-off achieving PSA25 (i.e. reductions of ≥25% in PSA), 63% PSA50,

Wed, 05 Aug 2026 09:02:00 -0400

HIGHLIGHTS

Preliminary assessment of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose cohorts

Nineteen participants from the SECuRE trial (NCT04868604)^[1] were included in this assessment of the safety and efficacy of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from the ongoing Cohort Expansion phase (data cut-off: July 20, 2026). The SECuRE trial continues to recruit new and treat existing participants in the Cohort Expansion phase.
Prostate-specific antigen (PSA) declines were substantial with 74% of evaluable participants at data cut-off achieving PSA25 (i.e. reductions of ≥25% in PSA), 63% PSA50,

Wed, 05 Aug 2026 09:02:00 -0400

HIGHLIGHTS

Preliminary assessment of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose cohorts

Nineteen participants from the SECuRE trial (NCT04868604)^[1] were included in this assessment of the safety and efficacy of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from the ongoing Cohort Expansion phase (data cut-off: July 20, 2026). The SECuRE trial continues to recruit new and treat existing participants in the Cohort Expansion phase.
Prostate-specific antigen (PSA) declines were substantial with 74% of evaluable participants at data cut-off achieving PSA25 (i.e. reductions of ≥25% in PSA), 63% PSA50,

Wed, 05 Aug 2026 09:02:00 -0400

HIGHLIGHTS

Preliminary assessment of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose cohorts

Nineteen participants from the SECuRE trial (NCT04868604)^[1] were included in this assessment of the safety and efficacy of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from the ongoing Cohort Expansion phase (data cut-off: July 20, 2026). The SECuRE trial continues to recruit new and treat existing participants in the Cohort Expansion phase.
Prostate-specific antigen (PSA) declines were substantial with 74% of evaluable participants at data cut-off achieving PSA25 (i.e. reductions of ≥25% in PSA), 63% PSA50,

Wed, 05 Aug 2026 09:02:00 -0400

HIGHLIGHTS

Preliminary assessment of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose cohorts

Nineteen participants from the SECuRE trial (NCT04868604)^[1] were included in this assessment of the safety and efficacy of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from the ongoing Cohort Expansion phase (data cut-off: July 20, 2026). The SECuRE trial continues to recruit new and treat existing participants in the Cohort Expansion phase.
Prostate-specific antigen (PSA) declines were substantial with 74% of evaluable participants at data cut-off achieving PSA25 (i.e. reductions of ≥25% in PSA), 63% PSA50,

Wed, 05 Aug 2026 09:02:00 -0400

HIGHLIGHTS

Preliminary assessment of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose cohorts

Nineteen participants from the SECuRE trial (NCT04868604)^[1] were included in this assessment of the safety and efficacy of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from the ongoing Cohort Expansion phase (data cut-off: July 20, 2026). The SECuRE trial continues to recruit new and treat existing participants in the Cohort Expansion phase.
Prostate-specific antigen (PSA) declines were substantial with 74% of evaluable participants at data cut-off achieving PSA25 (i.e. reductions of ≥25% in PSA), 63% PSA50,

Wed, 05 Aug 2026 09:02:00 -0400

HIGHLIGHTS

Preliminary assessment of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose cohorts

Nineteen participants from the SECuRE trial (NCT04868604)^[1] were included in this assessment of the safety and efficacy of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from the ongoing Cohort Expansion phase (data cut-off: July 20, 2026). The SECuRE trial continues to recruit new and treat existing participants in the Cohort Expansion phase.
Prostate-specific antigen (PSA) declines were substantial with 74% of evaluable participants at data cut-off achieving PSA25 (i.e. reductions of ≥25% in PSA), 63% PSA50,

Wed, 05 Aug 2026 09:02:00 -0400

HIGHLIGHTS

Preliminary assessment of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose cohorts

Nineteen participants from the SECuRE trial (NCT04868604)^[1] were included in this assessment of the safety and efficacy of the 8 GBq ⁶⁷Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from the ongoing Cohort Expansion phase (data cut-off: July 20, 2026). The SECuRE trial continues to recruit new and treat existing participants in the Cohort Expansion phase.
Prostate-specific antigen (PSA) declines were substantial with 74% of evaluable participants at data cut-off achieving PSA25 (i.e. reductions of ≥25% in PSA), 63% PSA50,